Physician profile
Louis E Cantor
NPI 1487655783
$532,101.59
in general payments reported to CMS, 2019-2025
14 companies · $20K in 2025
The $20K reported for 2025 was more than what 95% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91K · 2020: $110K · 2021: $73K · 2022: $161K · 2023: $73K · 2024: $2,755 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $95K · Food and Beverage: $778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $95,298.80 |
| Food and Beverage | $777.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $374,241.62 | 2019-2023 | Iolmaster 700, Artevo 800, Cirrus Hd-Oct |
| Sight Sciences, INC. | $131,704.57 | 2021-2024 | Omni Surgical System |
| Neurotech Pharmaceuticals, INC. | $19,950.00 | 2025 | Encelto |
| Abbvie INC. | $2,959.10 | 2023-2024 | Durysta |
| Allergan, INC. | $2,174.18 | 2019 | |
| Alcon Vision LLC | $254.25 | 2022-2024 | Hydrus Microstent |
| Bausch & Lomb Americas INC. | $241.05 | 2024-2025 | |
| Carl Zeiss Meditec USA, INC. | $150.93 | 2024 | Forum Glaucoma Workplace, Iolmaster 700 |
| Glaukos Corporation | $149.69 | 2019-2024 | |
| Aerie Pharmaceuticals, INC. | $140.87 | 2019-2021 | |
| Lensar, INC. | $71.75 | 2021 | |
| Novartis Pharmaceuticals Corporation | $28.44 | 2019 | |
| Ivantis, INC | $21.03 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Cantor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.